Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 3, 2014, Pages 280-287

  Berenguer, Juan ^a,b,o   Zamora, Francisco X ^c,d   Carrero, Ana ^a,b,o   Von Wichmann, Miguel A ^e   Crespo, Manel ^f   López Aldeguer, José ^g   Aldámiz Echevarría, Teresa ^a,b   Montes, Marisa ^c,d   Quereda, Carmen ^h   Téllez, María J ⁱ   Galindo, María J ^j   Sanz, José ^k   Santos, Ignacio ^l   Guardiola, Josep M ^m   Esteban, Herminia ⁿ   Bellón, José M ^a,b,o   González García, Juan ^c,d   Miralles, P ^o   Cosin J ^o   Lopez J C ^o   Padilla, B ^o   Parras, F ^o   Aldamiz Echevarria T ^o   Tejerina, F ^o   Gutierrez I ^o   Ramirez M ^o,t   Carretero, S ^o   Alvarez Pellicer, J ^p   Rodriguez E ^p   Arribas, J R ^p   Montes, M L ^p   Bernardino, I ^p   Pascual, J F ^p   Zamora, F ^p   Pena J M ^p   Arnalich, F ^p   Diaz M ^p   Gonzalez Garcia J ^p   Bustinduy, M J ^q   Iribarren, J A ^q   Rodriguez Arrondo F ^q   Von Wichmann, M A ^q   Blanes, M ^r   Cuellar, S ^r   Lacruz, J ^r   Montero, M ^r   Salavert, M ^r   Lopez Aldeguer J ^r   Callau, P ^s   Miro J M ^s   Gatell, J M ^s   Mallolas, J ^s   Ferrer, A ^t   Galindo, M J ^t   Van Den Eynde, E ^a   Perez M ^a   Ribera, E ^a   Crespo, M ^a   Vergas, J ^u   Tellez M J ^u   Casado, J L ^b   Dronda, F ^b   Moreno, A ^b   Perez Elias M J ^b   Sanfrutos, M A ^b   Moreno, S ^b   Quereda, C ^b   Jou, A ^v   Tural, C ^v   Arranz, A ^a   Casas, E ^c   De Miguel, J ^c   Schroeder, S ^c   Sanz, J ^c,d   Condes E ^w   Barros, C ^w   Santos, I ^d   Hernando, A ⁱ   Rodriguez V ⁱ   Rubio, R ⁱ   Pulido, F ⁱ   Domingo, P ^h   Guardiola, J M ^h   Ortiz, L ^x   Ortega, E ^x   Torres, R ^k   Cervero, M ^k   Jusdado, J J ^k   Rodriguez Zapata M ^m   Perez G ^y   Gaspar, G ^y   Barquilla, E ^t   Moyano, B ^t   Aznar, E ^t   Esteban, H ^t   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f Hospital Clínico Universitario   (United States)

^g Hospital Universitari Vall d'Hebron   (Venezuela)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL RAMÓN Y CAJAL   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^l HOSPITAL DE MÓSTOLES   (Spain)

^m HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o Hospital de la Santa Creu i Sant Pau   (Venezuela)

^p Hospital General Universitario   (Venezuela)

^q HOSPITAL SEVERO OCHOA   (Spain)

^r HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^s HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^t Fundacion Spanish Society of Infectious Diseases   (Spain)

^u HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^v HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^w HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^x HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^y HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

Administration and dosage; Chronic; Complications; Drug therapy; Follow up studies; Hepatitis C; HIV infections; Interferons; Therapeutic use; Treatment outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; INTERFERON;

ADULT; ARTICLE; ASCITES; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIMIT OF DETECTION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SUSTAIINED VIRAL RESPONSE; TREATMENT RESPONSE; VARICOSIS; VIRUS LOAD; BLOOD; COMPLICATION; DISEASE COURSE; DRUG COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; LIVER CIRRHOSIS; PATHOLOGY; PREDICTIVE VALUE; STATISTICAL MODEL; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84919687655     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000156     Document Type: Article

References (23)

1. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054-1058.
2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis. 2001;33:562-569.
3. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology. 2010;52:612-622.
4. Lin W, Weinberg EM, Chung RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis. 2013;207(suppl 1):S13-S18.
5. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med. 2006;166:1632-1641.
6. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D Study. AIDS. 2010;24:1537-1548.
7. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011;8:12-22.
8. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009;49:1605-1615.
9. Branch AD, Van Natta ML, Vachon ML, et al. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis. 2012;55:137-144.
10. Berenguer J, Alejos B, Hernando V, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS. 2012;26:2241-2246.
11. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
12. Van Der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-2593.
13. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407-413.
14. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2012;55:728-736.
15. Berenguer J, Alvarez-Pellicer J, Carrero A, et al. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus. J Hepatol. 2013;58:1104-1112.
16. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15-20.
17. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835-847.
18. Shiffman ML, Diago M, Tran A, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol. 2006;4:645-652.
19. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat. 2010;17:280-286.
20. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245-264.
21. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009, 50:1056-1063.
22. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-1713.
23. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308:370-378.